Charles River Labs AI Stock Analysis
Want to see CRL full AI Analyst Report?
Charles River Labs (CRL) AI Stock Analysis
Charles River Labs
(NYSE:CRL)
The score reflects a tug-of-war between pressured financial performance (notably weak recent revenue/profitability) and healthier forward indicators: solid cash generation, an improving outlook and sentiment from the latest earnings call (raised guidance, stronger bookings/backlog, margin expansion), and a technically strong uptrend. These positives are meaningfully offset by very expensive valuation (extremely high P/E) and ongoing segment headwinds (RMS softness, delayed pricing impact, higher interest expense).
Charles River Labs Key Performance Indicators (KPIs)
Revenue by SegmentBreaks down revenue across different business segments, highlighting which areas are driving growth and which may need strategic adjustments.
DSA is emerging as the primary growth engine — stronger bookings and a fatter backlog support management’s call for low-single-digit organic growth — while Manufacturing is generating outsized margin gains (helped by divestitures and cost actions) even as portfolio moves mute reported revenue. RMS remains the weak link, hit by North American academic/government funding and expected to decline low‑to‑mid single digits, capping near‑term top‑line. Raised EPS and cash targets lean on margin delivery, back‑loaded NHP sourcing benefits and timing of pricing recovery.
Charles River Labs (CRL) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $16.08B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.05M
- Price to Earnings (P/E)
- 328.7
- Beta (1Y)
- 0.65
- Revenue Growth
- -1.16%
- EPS Growth
- ―
- Country
- US
- Employees
- 19,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Charles River Labs Business Overview & Revenue Model
Company Description
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with d...
How the Company Makes Money
CRL makes money primarily by selling products and contracting services that customers use to advance research programs and move drug candidates toward clinical development. 1) Research Models and Services (RMS): - Product revenue: CRL generates reven...
Charles River Labs Earnings Call Summary
The call was predominantly positive. The company reported stronger-than-expected revenue, earnings, margins, bookings, backlog, and cash flow; raised full-year revenue and EPS guidance; and described improving biopharmaceutical demand, manufacturing momentum, strategic client expansion, and progress in modernization and scientific initiatives. The main challenges were the RMS decline, continued academic and government funding pressure, limited current pricing power, higher interest expense, and the remaining recovery in early-stage biotech activity.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, Charles River expects reported revenue decline of 1.5%-2%, organic revenue growth of at least 1.5%, DSA above 2% growth, manufacturing at a mid-single-digit growth rate, and RMS at a low single-digit organic decline; operating margin expansion of approximately 120-150 basis points; non-GAAP earnings per share of $11.35-$11.55, representing 10%-12% year-over-year growth; non-GAAP tax rate of approximately 23%; net interest expense at the upper end of $103 million-$108 million; unallocated corporate costs of approximately 6% of revenue; CapEx of approximately $200 million; and free cash flow of $400 million-$420 million. For the fourth quarter, it expects DSA organic growth at mid-single-digit and manufacturing at high single-digit rates, a modest reduction in the RMS growth rate, continued sequential operating margin improvement of approximately 150 basis points, manufacturing operating margin approaching 40%, and non-GAAP earnings per share growth of approximately 30%-40% year-over-year. For 2027, it expects a gradual improvement from the organic growth rate in 2026, with revenue growth increasing to the targeted 5%-7% range starting in 2028, and operating margin improvement higher than the 75 basis point average through 2030.
Charles River Labs Financial Statement Overview
Summary
Mixed fundamentals. Income statement trends are weak (sharp TTM revenue contraction, compressed profitability with negative EBIT and losses/near-breakeven), but cash flow remains a clear strength (solid TTM operating cash flow and free cash flow) and the balance sheet is serviceable though meaningfully leveraged, making earnings recovery important.
Income Statement
34NegativeBalance Sheet
55NeutralCash Flow
72Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.98B | 4.02B | 4.05B | 4.13B | 3.98B | 3.54B |
| Gross Profit | 1.31B | 1.23B | 1.33B | 1.50B | 1.46B | 1.33B |
| EBITDA | 293.19M | 410.84M | 581.14M | 1.03B | 986.15M | 820.16M |
| Net Income | 40.19M | -144.34M | 10.30M | 474.62M | 486.23M | 390.98M |
Balance Sheet | ||||||
| Total Assets | 7.45B | 7.14B | 7.53B | 8.20B | 7.60B | 7.02B |
| Cash, Cash Equivalents and Short-Term Investments | 200.38M | 213.77M | 194.61M | 276.77M | 233.91M | 246.30M |
| Total Debt | 2.85B | 3.07B | 2.72B | 3.07B | 3.10B | 3.21B |
| Total Liabilities | 4.18B | 3.92B | 4.02B | 4.54B | 4.58B | 4.43B |
| Stockholders Equity | 3.23B | 3.16B | 3.46B | 3.60B | 2.98B | 2.53B |
Cash Flow | ||||||
| Free Cash Flow | 399.63M | 518.49M | 501.61M | 365.37M | 294.91M | 532.03M |
| Operating Cash Flow | 622.41M | 737.65M | 734.58M | 683.90M | 619.64M | 760.80M |
| Investing Cash Flow | -443.19M | -209.32M | -245.09M | -563.15M | -607.92M | -1.44B |
| Financing Cash Flow | -122.95M | -536.73M | -550.93M | -85.52M | -42.40M | 672.60M |
Charles River Labs Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRL, the sentiment is Neutral. The current price of 335.52 is below the 20-day moving average (MA) of 344.72, above the 50-day MA of 312.00, and above the 200-day MA of 228.34, indicating a neutral trend. The MACD of 7.21 indicates Positive momentum. The RSI at 51.46 is Neutral, neither overbought nor oversold. The STOCH value of 52.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CRL.
Charles River Labs Risk Analysis
Charles River Labs disclosed 41 risk factors in its most recent earnings report. Charles River Labs reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksCharles River Labs Peers Comparison
Overall Rating
MEDP84Outperform
TMO76.9Outperform
LH75Outperform
IQV74Outperform
ICLR71Outperform
CRL62Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 84Outperform | $18.13B | 35.47 | 99.76% | ― | 20.35% | 25.24% | |
| 77Outperform | $256.15B | 36.40 | 13.31% | 0.27% | 8.27% | 9.59% | |
| 75Outperform | $30.24B | 30.30 | 11.54% | 0.77% | 6.02% | 19.63% | |
| 74Outperform | $43.63B | 31.85 | 21.82% | ― | 8.88% | 13.11% | |
| 71Outperform | $14.34B | 32.76 | 4.85% | ― | 0.67% | 43.70% | |
| 62Neutral | $16.08B | 328.75 | 1.32% | ― | -1.16% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CRL | Charles River Laboratories Intl | 335.52 | 173.88 | 107.57% | |
| ICLR | Icon Plc | 191.40 | 32.59 | 20.52% | |
| LH | Labcorp Holdings Inc. | 372.46 | 114.52 | 44.40% | |
| TMO | Thermo Fisher Scientific | 691.33 | 119.55 | 20.91% | |
| IQV | IQVIA Holdings | 264.73 | 47.25 | 21.73% | |
| MEDP | Medpace Holdings Inc | 648.20 | 56.02 | 9.46% |
Charles River Labs Corporate Events
Charles River Labs to Acquire Frontage Bioanalysis Operations
PositiveOn November 9, 2026, Charles River announced definitive agreements to acquire Frontage Holdings’ bioanalysis and DMPK operations in Exton, Pennsylvania, for approximately $470 million in cash. The assets include bioanalysis, biomarker and DMPK testin...
Charles River Labs Unveils New Strategic Growth Vision
PositiveOn September 24, 2026, Charles River Laboratories used its Investor Day to unveil a refreshed “Pathway to Purpose” strategic vision aimed at modernizing operations, strengthening its scientific portfolio, and enhancing its client-centric model to rei...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
